van Lieshout, Marloes
Luman, Marjolein
Twisk, Jos W. R.
Faraone, Stephen V.
Heslenfeld, Dirk J.
Hartman, Catharina A.
Hoekstra, Pieter J.
Franke, Barbara
Buitelaar, Jan K.
Rommelse, Nanda N. J.
Oosterlaan, Jaap
Funding for this research was provided by:
National Institutes of Health (R01MH62873)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (1750102007010)
Netherlands Organisation for Health Research and Development (60-60600-97- 193)
Article History
First Online: 9 July 2016
Compliance with Ethical Standards
:
: MvL, ML, JWRT, DJH, HvE, APG, AJAMT, CH, BF, NNJR, and JO report no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: In the past year, SVF received income, potential income, travel expenses and/or research support from Pfizer, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA Pharma, Neurovance, Impax, NeuroLifeSciences. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received or research support from: Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. SVF receives royalties from books published by Guilford Press: <i>Straight Talk about Your Child</i>’<i>s Mental Health</i>, Oxford University Press: <i>Schizophrenia</i>: <i>The Facts</i> and Elsevier, <i>ADHD</i>: <i>Non-Pharmacologic Interventions</i>. PJH has been in the past 3 years a paid member of advisory board of Shire. JKB has been in the past 3 years a consultant to, member of advisory board of, and/or speaker for: Janssen Cilag BV, Eli Lilly, Shire, Novartis, Medice, Roche, Vifor, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties.